Proposal to Refuse to Approve a New Drug Application for TRADIPITANT; Opportunity for a Hearing
Published Date: 1/16/2025
Notice
Summary
The FDA is thinking about saying no to Vanda Pharmaceuticals' new drug, TRADIPITANT, in its current form. Vanda can ask for a hearing to explain why the drug should be approved. If you want to speak up or support the hearing, you’ve got until mid-February and mid-March 2025 to send in your requests and info.
Analyzed Economic Effects
3 provisions identified: 1 benefits, 2 costs, 0 mixed.
FDA Identifies Major Data Gaps
FDA identified specific deficiencies in the submitted clinical and nonclinical data: Study 3301, Group 1 failed to show statistically significant efficacy versus placebo; Study 2301 had methodological shortcomings; post hoc analyses are insufficient; clinical safety data are limited to 12 weeks; and nonclinical studies did not adequately characterize long-term safety. FDA recommended Vanda conduct two new adequate and well-controlled trials in adults with idiopathic or diabetic gastroparesis and a chronic repeat-dose toxicity study in a nonrodent species to address these deficiencies.
FDA Proposes Refusal of TRADIPITANT
The FDA proposes to refuse approval of Vanda Pharmaceuticals' new drug application (NDA 218489) for TRADIPITANT capsules, 85 mg, in its present form because the agency found the application does not provide substantial evidence of effectiveness and does not demonstrate safety for the proposed use. If no timely hearing request is filed, FDA will issue a notice refusing to approve the application.
Hearing Opportunity and Deadlines
Vanda and other interested persons may request a hearing on FDA's proposal; hearing requests must be submitted by February 18, 2025, and supporting data, analyses, or other comments must be submitted by March 17, 2025. The notice warns that failure to request a hearing in the required manner and time will waive the opportunity and FDA will issue a refusal to approve the application.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Related Federal Register Documents
2026-13436 — Polyvinyl Alcohol From China and Japan; Scheduling of Expedited Five-Year Reviews
The U.S. International Trade Commission is speeding up its review to decide if special taxes on polyvinyl alcohol from China and Japan should continue. This affects companies that make or sell this material in the U.S. The review started on June 5, 2026, and could impact prices and trade rules soon.
2026-13431 — Submission for Review: Report of Medical Examination of Person Electing Survivor Benefits, OPM 1530, 3206-0162
If you’re applying for survivor benefits from the federal government, you might need to fill out a medical exam report form. The Office of Personnel Management is asking for public feedback on this form to make sure it’s clear and not too much work. Comments are open until August 3, 2026, so now’s the time to speak up if you have ideas or concerns!
2026-13480 — Government Owned Invention Available for License: A Conserved Viral Peptide for Use in Cancer Immunotherapy
The National Cancer Institute has created a special viral peptide that could help prevent and treat a serious liver cancer called HCC. This new discovery might lead to a vaccine or therapy that boosts the immune system to fight cancer better. Researchers and companies interested in developing this treatment can now license the technology, opening doors for faster progress and potential health benefits worldwide.
2026-13453 — Privacy Act of 1974; System of Records
The Department of Veterans Affairs is updating its system that tracks debts from VA benefits like education, compensation, and loans. If you owe money to the VA, this change affects how your info is stored and used. You have 30 days to share your thoughts before the update goes live, but no extra costs or delays are expected.
2026-13466 — Notice of Renewal of the MCC Advisory Council and Call for Nominations
The Millennium Challenge Corporation (MCC) has renewed its Advisory Council for 2026-2028 and is looking for new members from private companies with skills in areas like technology, finance, and infrastructure. This group helps MCC fight poverty by giving smart advice on projects in developing countries. If you want to join, send your nomination by August 7, 2026, and get ready to meet up to four times a year, either in person or online.
2026-13432 — Submission for Review: Initial Certification of Full-Time School Attendance, RI 25-41, 3206-0099
The Office of Personnel Management is asking for public feedback on a form that proves kids are attending school full-time, which helps determine survivor benefits. This review affects families receiving these benefits and aims to keep the form clear and easy to use. Comments are open until August 3, 2026, so now’s the time to speak up and help shape the process!
Previous / Next Documents
Previous: 2025-01026 — Proposed Flood Hazard Determinations
FEMA is updating flood risk maps for several communities, which could change flood zones and insurance rules. If you live in these areas, your flood insurance costs or building rules might change. You’ve got until April 16, 2025, to check the new maps and share your thoughts before the updates become official.
Next: 2025-01028 — Recommendations To Reduce the Risk of Transfusion-Transmitted Malaria; Draft Guidance for Industry; Availability
The FDA is rolling out new draft rules to help blood banks better spot and stop malaria from sneaking into blood donations. Blood centers will start using special tests to check donors who might have malaria, making transfusions safer for everyone. If you’re involved in blood collection, get ready to share your thoughts by March 17, 2025, before these changes become official!